Every September, the world observes World Alzheimer’s Day, a global moment to confront the condition that remains one of the most significant health challenges of our time. On September 21, 2026, the focus sharpens under a theme that speaks directly to the power of timely action: “The Earlier You Know, The More You Can Do: A Dementia Diagnosis Matters.” This message, from Alzheimer’s Disease International (ADI), is not merely a slogan; it is a call to dismantle the silence, stigma, and delay that too often define the dementia journey.
The scale of the challenge is staggering. More than 57 million people worldwide currently live with dementia, with nearly 10 million new cases diagnosed each year. Alzheimer’s disease is the most common form, accounting for an estimated 60 to 70 percent of all cases. In the United States alone, the Alzheimer’s Association reports that more than 55 million people are affected globally, and one in three older adults dies with Alzheimer’s or another dementia. These numbers are not abstract; they represent millions of families navigating a landscape of confusion, fear, and often, prolonged uncertainty.
The 2026 campaign zeroes in on a critical gap: the diagnosis itself. On average, it takes 3.5 years for a person to receive a dementia diagnosis after symptoms first emerge, and an estimated 75 percent of people living with dementia remain undiagnosed. This delay is not a neutral waiting period. It is a window of opportunity lost, a time when families could be planning, accessing support, and making informed decisions while cognition still allows for meaningful participation.
Why does an early diagnosis matter so profoundly? The answer lies in the fundamental difference between proactive care and reactive crisis management. An early diagnosis provides access to treatment that can slow the rate of decline and, in some cases, disease-modifying therapies may be considered for eligible patients. It opens doors to clinical trials for emerging treatments, giving individuals a chance to contribute to the science that may one day yield a cure. Crucially, it allows families to make legal, financial, and long-term care plans while the person with dementia can still articulate their wishes and preferences.
The benefits extend beyond the individual. An early diagnosis enables better access to support services, reduces the strain on caregivers, and can improve overall quality of life through both pharmacological and non-pharmacological interventions. As Professor Hanadi Al Hamad of Hamad Medical Corporation explains, “Early diagnosis of dementia is a vital step in ensuring that patients and their families receive the appropriate assessment, care, and support in a timely manner”.
Advances in diagnostic technology are making early detection more accessible than ever. Blood-based biomarkers, such as the pTau217 test, are now offering minimally invasive alternatives to costly and hard-to-access PET scans, with accuracy comparable to spinal fluid diagnostics. AI-powered blood tests have achieved diagnostic accuracy rates of over 92 percent, and new models can predict the onset of symptoms within three to four years using a single blood test. These innovations are not just scientific milestones; they are practical tools that can transform how and when dementia is identified.
Yet, awareness remains the first and most critical step. The warning signs of Alzheimer’s are often dismissed as normal aging: misplacing items, forgetting names, struggling with familiar tasks. The distinction is crucial: normal aging involves temporary forgetfulness, while Alzheimer’s brings persistent, progressive decline that disrupts daily life. When families recognize these signs and seek assessment, they are not giving up hope; they are seizing it.
This World Alzheimer’s Day, the message is clear: knowledge is not a burden. It is power. A diagnosis is not an ending; it is a beginning of informed choices, of support, of connection, and of the possibility to live well for as long as possible. The earlier you know, the more you can do.
Assistant Professor at the University of Social Welfare and Rehabilitation Sciences in Tehran, Iran. He earned his Ph.D. in Gerontology with honors in 2017, following his Bachelor's and Master's degrees in Rehabilitation Sciences. Dr. Rashedi is an esteemed member of several prestigious organizations, including the Gerontological Society of America (GSA), the International Society to Advance Alzheimer's Research and Treatment (ISTAART), and the American Psychological Association (APA). His research primarily focuses on mental health and psychogeriatrics. Since 2019, Dr. Rashedi has been a Senior Collaborator for the Global Burden of Disease (GBD) at the Institute for Health Metrics Evaluation (IHME) at the University of Washington in the United States.